Cohen-Bucay Abraham, Gordon Craig E, Francis Jean M
Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080, Mexico.
Nephrology Department, American British Cowdray Medical Center, Mexico City, 05300, Mexico.
F1000Res. 2019 Feb 18;8. doi: 10.12688/f1000research.16627.1. eCollection 2019.
Kidney transplantation (KT) is the most effective way to decrease the high morbidity and mortality of patients with end-stage renal disease. However, KT does not completely reverse the damage done by years of decreased kidney function and dialysis. Furthermore, new offending agents (in particular, immunosuppression) added in the post-transplant period increase the risk of complications. Cardiovascular (CV) disease, the leading cause of death in KT recipients, warrants pre-transplant screening based on risk factors. Nevertheless, the screening methods currently used have many shortcomings and a perfect screening modality does not exist. Risk factor modification in the pre- and post-transplant periods is of paramount importance to decrease the rate of CV complications post-transplant, either by lifestyle modification (for example, diet, exercise, and smoking cessation) or by pharmacological means (for example, statins, anti-hyperglycemics, and so on). Post-transplantation diabetes mellitus (PTDM) is a major contributor to mortality in this patient population. Although tacrolimus is a major contributor to PTDM development, changes in immunosuppression are limited by the higher risk of rejection with other agents. Immunosuppression has also been implicated in higher risk of malignancy; therefore, proper cancer screening is needed. Cancer immunotherapy is drastically changing the way certain types of cancer are treated in the general population; however, its use post-transplant is limited by the risk of allograft rejection. As expected, higher risk of infections is also encountered in transplant recipients. When caring for KT recipients, special attention is needed in screening methods, preventive measures, and treatment of infection with BK virus and cytomegalovirus. Hepatitis C virus infection is common in transplant candidates and in the deceased donor pool; however, newly developed direct-acting antivirals have been proven safe and effective in the pre- and post-transplant periods. The most important and recent developments on complications following KT are reviewed in this article.
肾移植(KT)是降低终末期肾病患者高发病率和死亡率的最有效方法。然而,肾移植并不能完全逆转多年肾功能下降和透析所造成的损害。此外,移植后添加的新的致病因素(特别是免疫抑制)会增加并发症的风险。心血管(CV)疾病是肾移植受者的主要死因,需要根据危险因素进行移植前筛查。然而,目前使用的筛查方法存在许多缺点,且不存在完美的筛查方式。移植前后的危险因素修正对于降低移植后心血管并发症的发生率至关重要,可通过生活方式改变(如饮食、运动和戒烟)或药物手段(如他汀类药物、抗高血糖药物等)来实现。移植后糖尿病(PTDM)是该患者群体死亡的主要原因。虽然他克莫司是PTDM发生的主要因素,但由于使用其他药物会增加排斥反应的风险,免疫抑制的改变受到限制。免疫抑制还与较高的恶性肿瘤风险有关;因此,需要进行适当的癌症筛查。癌症免疫疗法正在彻底改变普通人群中某些类型癌症的治疗方式;然而,其在移植后的使用受到同种异体移植排斥风险的限制。正如预期的那样,移植受者也面临较高的感染风险。在护理肾移植受者时,在筛查方法、预防措施以及BK病毒和巨细胞病毒感染的治疗方面需要特别关注。丙型肝炎病毒感染在移植候选者和已故供体库中很常见;然而,新开发的直接作用抗病毒药物已被证明在移植前后均安全有效。本文综述了肾移植后并发症的最重要和最新进展。